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BacKGrOUnd
These are exciting times in the field of plastic and reconstructive surgery. Meaningful advances in 
a wide range of basic science and clinical spheres have been made in the field in recent years, with 
direct translation to patient care. As a community, we are fortunate to be involved in such a vast, 
complex, increasingly interdisciplinary, rapidly expanding, and intellectually challenging field of 
surgery. Plastic surgery aims to restore “form and function” following a wide range of congenital or 
acquired defects, with procedures often transcending anatomic boundaries. This versatility promotes 
innovation, and with the recent advances in medical imaging (1), microsurgery (2), composite tissue 
allotransplantation (3, 4), nanotechnology (5), cell biology and biomaterials (6), and 3D printing 
(7), treatment options for patients are wider than ever before. For centuries, the “reconstructive 
ladder” was restricted to local flaps and skin grafts. Although these autologous options are reliable, 
plastic surgeons, with their constant wish to refine techniques, have become increasingly cognizant 
that there is the real potential for a paradigm shift in reconstructive surgery in the medium term. 
Tissue-engineered solutions (Figure 1A) offer the potential to alleviate the need for donor sites and 
their associated morbidity and to reduce hospital stay and associated costs (8).
eXtent OF the prOBleM
Reconstructive plastic surgeons have a diverse workload and contrary to the perceptions of the 
media, it comprises a relatively small proportion of purely aesthetic procedures (9). The major-
ity of operations relate to wound management and neoplasia, with a significant health economic 
impact (9). In the year 2013–2014 alone, over one million patients were treated in NHS England by 
plastic surgeons (10, 11). Evidence suggests that this workload will continue to increase (12). With 
a continual supply of major trauma and neoplasia, plastic surgeons are facing more challenging 
composite defects than ever before coupled with internet and media savvy patients with increasing 
expectations (13).
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innOVatiOnS in recOnStrUctiVe 
SUrGery
Technological innovation in plastic and reconstructive surgery 
in the twentieth century revolutionized the specialty, opening 
up the possibility for surgeons to operate on microvascular 
structures using specialized microscopes and instruments, ena-
bling them to undertake free tissue transfers (2) and extremity 
replantations. Despite these developments in practice, we are 
still confronted with shortcomings relating to the availability 
of donor tissues. In order to overcome this, novel approaches 
have been investigated. Transplantation of organs and tissues, 
first performed by a plastic surgeon and Nobel laureate (Dr. 
Joseph Murray) in 1954 (14, 15), has rapidly expanded over the 
twentieth century from traditional solid organ transplant to a 
range of vascularized composite tissue allografts including the 
upper extremity (3) and face (4). Although excellent medium-
term outcomes have been reported, there have been ongoing 
debates surrounding ethical (16, 17), psychological, and medical 
issues in the long term, especially relating to the effects of immu-
nosuppression (18). The more attractive concept, obviating the 
need for long-term immunosuppression, is tissue engineering. 
The Medical Research Council states that regenerative medicine 
and tissue engineering “holds the promise of revolutionizing 
patient care in the twenty-first century” and the UK government 
highlighted regenerative medicine as one of the key areas, which 
could provide a global competitive advantage for the UK (19, 20). 
In 2014, it was highlighted as one of the eight great technolo-
gies in the industrial strategy government manifesto worthy of 
significant investment.
the challenGeS
Tissue engineering is a modern, interdisciplinary field combining 
principles of engineering, physics, and life sciences. It shares a 
common objective with plastic and reconstructive surgery: “to 
restore form and function” (21, 22). The surgical community 
worldwide is becoming increasingly aware of the research 
landscape. The American Society of Plastic surgeons have 
highlighted the role of tissue engineering in the future of plastic 
surgery (23), particularly the need for a focus on translation from 
bench research to clinical practice, which would provide clarity 
on avenues for upscaling and tissue engineering supply chains 
(Figure 1B).
Although the UK government and others have recognized 
the potential of regenerative medicine and tissue engineering to 
impact on the health service, they also highlighted the current 
“lack of coordination” in the field as a whole (24). Despite recent 
FiGUre 1 | (a) Tissue-engineered reconstructive solutions. (B) Potential barriers to translation at each level of the tissue-engineering supply chain.
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in  vitro and in  vivo studies attesting to the feasibility of tissue 
engineering for use in a range of clinical scenarios (25–30), bar-
riers have been identified that are inhibiting clinical translation 
(Figure 1B). These barriers to translation are deep rooted at the 
basic science level, manifesting in insufficient understanding of 
the safety and durability of tissue-engineered constructs (31, 32). 
Understandably, before these hurdles are overcome, investors 
are unwilling to shoulder the financial, ethical, and regulatory 
burden of translational research that may not be commercially 
viable, which then impacts on funding and further progress in 
the field (33).
Scientific Unknowns
The term “tissue engineering” was first coined almost 30 years 
ago, with skin being one of the first to be used clinically (34). 
Despite numerous successes in this exciting field, there have been 
very few reports of successful clinical translation. This is due to 
a combination of factors, including lack of clarity regarding ideal 
cell sources and scaffolds (35), methods of vascularizing larger 
constructs (36), reliable cell and construct characterization pre-
implantation and evidence of safety (37), and durability in large 
animal models (35). This is not surprising given the complexity of 
research in this field that cross cuts cell biology, material science, 
biochemistry, and engineering. As cells are complex, dynamic, 
and interactive, it is crucial to have a solid scientific founda-
tion regarding their stability, functional capacity, and response 
to host environment (38). It is generally accepted that it takes 
20–30  years from the start of basic science research to clinical 
utility, demonstrated by contemporary treatments such as bone 
marrow transplantation (39).
ethical and regulatory Milestones
There is a lack of international standards for the use of stem cell and 
tissue engineering therapies in human patients, which has led to 
the use of unproven treatments in unregulated international clinics 
which damages the research in this field (40, 41). Stem cell hype 
has also generated unrealistic patient hopes, which raises ethical 
concerns when initiating clinical trials of cell-based therapies (42). 
Tissue-engineered constructs do not easily fit into the U.S. Food 
and Drug Administration (FDA) and the European Medicines 
Agency (EMA) classifications for medical products (43). Since 
many of these constructs are complex and consist of more than 
one component, i.e., biomolecule, cell, and biomaterial, they are 
classed as combination products that fall under the advanced 
therapy medicinal products (ATMPs) category (44, 45). The review 
of any regulated product is therefore undertaken on a case-by-case 
basis but generally considers four aspects: product manufacture, 
preclinical testing (laboratory and animal models), clinical perfor-
mance, and product labeling according to claim of intended use. 
These processes are time, labor, and money intensive and have often 
been criticized for lack of clarity and inconsistencies between dif-
ferent regulatory agencies (46, 47), which have in turn hindered the 
availability of products in some areas. The tissue-engineering field 
is still in early development and hence regulatory requirements are 
also continuing to evolve with it. There is now increasing dialog 
between the international TERMIS committees and regulatory 
bodies in order to work toward a consensus on regulatory require-
ments in order to foster innovation while continuing to ensure the 
safety and efficacy of tissue-engineered solutions (46).
lack of Funding
Despite investment in the tissue-engineering sector from a num-
ber of companies, the high production costs, unrealistic promises 
from the scientific community, and regulatory hurdles have 
limited successful clinical translation and commercial success of 
these early products (48–50). It has been suggested that alliances 
between companies or collaboration between industry and gov-
ernment funding agencies, who can share expertise as well as the 
financial burden, will be the key to driving translation from bench 
to bedside through clinical trials (33, 49). Partnerships within and 
across different sectors, such as the CASMI Translational Stem 
Cell Consortium (CTSCC) (51) (an academic-industry consor-
tium), are already emerging and aim to identify key hurdles in 
commercialization. There is also an increasing focus on devel-
oping “translation centers” such as Harvard Stem Cell Institute 
(HSCI), Centre for Commercialisation of Regenerative Medicine 
(CCRM), and the Cell Therapy Catapult (51).
infrastructure for Scale Up  
and Scale Out
Biomanufacturing is an often overlooked but vital process of 
clinical translation (52). Once a successful tissue-engineered con-
struct has been developed and tested in the laboratory, there are a 
number of considerations when driving the product toward clini-
cal trials and widespread commercial use. Many methods of cell 
isolation, expansion, differentiation, and seeding onto scaffolds 
continue to be variable bench processes. These processes need 
to be refined by using batch-tested reagents, defined culture and 
bioreactor conditions, and automated techniques to ensure the 
process is quality controlled and able to be verified and validated 
according to regulatory requirements (38). A key component is the 
transition from manual laboratory based techniques to certified 
good manufacturing practice (cGMP) processes, which require a 
sound business model, significant infrastructure, personnel and 
automated scale-up and scale-out strategies. In order to set up 
these processes for widespread use in health services, there needs 
to be synergized communication between basic researchers, clini-
cians, industry experts, and regulators. There are initiatives to set 
up translational hubs for ATMPs, such as the European Advanced 
Translational Research Infrastructure in Medicine (EATRIS), in 
order to fill the gap between basic science and clinical practice 
and overcome the bottlenecks for translation (45).
cOnclUSiOn
There is a clear and unmet clinical need for an adequate solu-
tion to reconstruct tissue defects following tumor resections, 
severe trauma, or deep burns, which removes the morbidity 
and mortality associated with donor sites. Tissue engineering, 
with its potential to biomanufacture constructs to repair and 
restore complex defects, holds great promise (53). The innova-
tive and complex nature of these constructs results in a number 
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of scientific, ethical, regulatory, financial, and infrastructural 
challenges, which currently hinder clinical translation. Answers 
to the fundamental scientific questions as well as our ability to 
overcome the translational challenges rely on multidisciplinary 
working groups (academia, clinicians, patient representatives, 
investors, manufacturing experts, and regulators) as well as 
governmental support (54) before we will see widespread use of 
tissue-engineered constructs in reconstructive surgery.
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